Life Science Legal Strategy Summit

Fish & Richardson attorneys Douglas McCann, Dexter Whitley, and Brian Coggio will speak at the Kisaco Life Science Legal Strategy Summit on October 13 and 14, 2026.  

Fish is a proud supporter of this year’s summit, which features interdisciplinary legal content focused on the life sciences strategy sector and on IP, regulatory, competition, and corporate law. Session details are below. 

Designing and Disputing Divisional Portfolios: New Insights at the Interface Between IP and Antitrust | Douglas McCann 

Divisional filing strategies have become a crucial and often contentious issue at the intersection between life science IP and antitrust law. This session will define the legal boundaries between anti-competitive evergreening and strategic portfolio optimization, discuss how divisional filing strategies should be aligned with regulatory exclusivity and SPC frameworks, and explore the most effective approaches for generics companies seeking to challenge access blocking divisional patent families. 

Second Medical Use and Skinny Labelling: Building a Robust IP and Exclusivity Strategy | Dexter Whitley 

Second medical use patents remain one of the most commercially sensitive tools in the originator playbook. Yet they are among the most volatile of protection mechanisms when it comes to validity challenge and “skinny labelling” carve-out strategies. This session will explore the latest case law updates and patentability challenges in the European, U.S., and Brazilian second medical use and skinny labelling spaces, covering new strategies for building and attacking these patents. 

Beyond Patents: The Management and Strategic Role of Trade Secrets in the Life Sciences | Brian Coggio

Trade secret protection is becoming an increasingly critical component of life sciences IP strategy, as companies reassess the boundaries between patent protection, regulatory disclosure, and confidential know-how. This roundtable will examine how organizations are structuring trade secret frameworks within their wider IP portfolio and how legal teams are navigating the tension between disclosure requirements and long-term competitive advantage. 

For more information, click here.